Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.

In the phase 3 trial comparing eribulin to capecitabine, a numerical trend favoring eribulin in OS was noted, that was not statistically significant [ 14 ].

also in 1,012 other papers

Survival analysis for the three treatments stratified by hormone receptor subtype showed a trend favoring eribulin within the TNBC patient subtype compared to gemcitabine [HR (95% CI) 0.82 (0.51, 1.30)] and capecitabine [HR (95% CI) 0.77 (0.43, 1.38)], though it was not statistically significant.

also in 53,322 other papers